Welcome to our dedicated page for Aadi Bioscience news (Ticker: AADI), a resource for investors and traders seeking the latest updates and insights on Aadi Bioscience stock.
Aadi Bioscience, Inc. (Nasdaq: AADI) is a precision oncology company whose news flow reflects both commercial-stage activity and a significant strategic transformation. Company press releases describe Aadi as focused on applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers.
News coverage for AADI has included financial results and earnings updates, such as quarterly reports highlighting FYARRO® product sales and operating performance. Investors can also find announcements about upcoming webcasts where Aadi discusses quarterly and full-year results and provides corporate updates.
A key theme in recent Aadi news has been its business transformation. The company has reported a strategic plan involving the sale of its FYARRO business and associated infrastructure to KAKEN Pharmaceutical, the in-licensing of a three-asset, preclinical antibody-drug conjugate (ADC) portfolio from WuXi Biologics and HANGZHOU DAC, and a PIPE financing. Related news items include the filing of a definitive proxy statement, the scheduling and outcome of a Special Meeting of Stockholders, and the closing of the PIPE financing.
Additional AADI news highlights pipeline and clinical developments, such as updates on the PRECISION1 tumor-agnostic trial of nab-sirolimus and decisions to halt or adjust trials based on data and strategic priorities. The company also issues releases on leadership and governance changes, including the appointment of a Chief Scientific Officer with extensive ADC experience and the addition of board members with backgrounds in ADC development.
For investors and followers of oncology therapeutics, the AADI news stream provides insight into how the company is shifting from FYARRO commercialization toward an in-licensed ADC portfolio, while managing capital through private placements and strategic transactions. Regular news items offer context on Aadi’s evolving pipeline, financing activities, and corporate direction.
Aadi Bioscience, Inc. (NASDAQ: AADI) has announced its participation in the 43rd Annual Healthcare Conference from March 6-8, 2023, in Boston, MA. CEO Brendan Delaney will join a panel titled 'Tumor Agnostic Development' on March 8, 2023, at 9:10 AM ET. The event will be webcast live on the company's investor relations website and available for replay for 30 days. Aadi focuses on precision therapies targeting genetically-defined cancers, having received FDA approval for its drug FYARRO® for advanced tumors. The company is also conducting the PRECISION 1 trial for tumors with specific genetic alterations.
Aadi Bioscience has presented three clinical trial posters at the CTOS 2022 Annual Meeting. Highlighted were the trial-in-progress for PRECISION 1, aimed at treating solid tumors with TSC1/TSC2 alterations, and the AMPECT trial's long-term results. The AMPECT study noted a median Duration of Response (DoR) exceeding 3 years and Overall Survival (OS) of 53.1 months. The data also underscored the safety profile of nab-sirolimus, with manageable adverse events not affecting treatment efficacy. These findings bolster Aadi's position in precision oncology.
Aadi Bioscience (AADI) announced a significant corporate update, highlighting a successful $72.5 million PIPE financing that extends its cash runway into 2025. The company reported a 24% increase in FYARRO® (nab-sirolimus) sales, totaling $4.2 million for Q3 2022. The PRECISION 1 trial is on track, with preliminary data expected in H1 2023. A leadership transition is set for January 1, 2023, with Neil Desai becoming Executive Chairman and Brendan Delaney stepping in as CEO. Aadi has also signed a collaboration with Mirati Therapeutics to study the combination of adagrasib and nab-sirolimus.
Aadi Bioscience announced a leadership transition, with Neil Desai becoming Executive Chairman and Brendan Delaney promoted to President and CEO, effective January 1, 2023. Desai has led the company since its inception, guiding the approval of FYARRO for advanced malignant PEComa and initiating the PRECISION 1 trial for broader cancer indications. The transition comes as Aadi has grown significantly, raising $155M during its public listing in August 2021 and $72.5 million in September 2022. Delaney previously held executive roles at Constellation Pharma and Immunomedics, bringing extensive commercial experience.
Aadi Bioscience, a biopharmaceutical company focused on precision therapies for genetically defined cancers, will present at three major conferences in November 2022. These include the H.C. Wainwright Precision Oncology Virtual Conference on November 14, the Jefferies London Healthcare Conference from November 15-17, and the Piper Sandler Healthcare Conference from November 29 to December 1. CEO Neil Desai and COO Brendan Delaney will engage in discussions highlighting the company's advancements, including the FDA-approved FYARRO® treatment for certain cancer patients.
Aadi Bioscience, Inc. (NASDAQ: AADI) announced preclinical data showcasing the synergistic potential of combining KRAS inhibitors with nab-sirolimus for treating KRAS-mutated cancers. The data will be presented at the 34th EORTC-NCI-AACR Symposium in Barcelona on October 27, 2022. This study indicates that the combination significantly enhances response rates against KRAS G12C mutant lung and bladder cancers. Aadi aims to address adaptive resistance seen in KRAS mutations, emphasizing the role of nab-sirolimus in future clinical applications.
Mirati Therapeutics (MRTX) and Aadi Bioscience (AADI) announced a clinical collaboration on Oct. 12, 2022, to evaluate the combination of adagrasib, a KRASG12C inhibitor, and nab-sirolimus, an mTOR inhibitor, in patients with KRASG12C mutant non-small cell lung cancer (NSCLC). The Phase 1/2 trial aims to determine the optimal dosing, safety, and efficacy of the drug combination. Preclinical data showed enhanced anti-tumor efficacy when both agents were used together. The collaboration exemplifies their commitment to advancing targeted therapies for challenging cancers.
Aadi Bioscience, Inc. (NASDAQ: AADI) announced a private investment in public equity (PIPE) financing, issuing 3,373,526 shares at $12.50 each, and pre-funded warrants for up to 2,426,493 shares at $12.4999 per share. The gross proceeds are expected to be around $72.5 million, aimed at extending cash reserves into 2025. The funds will support the PRECISION 1 trial and expand FYARRO commercial efforts. The PIPE is set to close on September 26, 2022, and includes participation from various investment groups.
Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focusing on precision therapies for cancers with mTOR pathway gene alterations, announced its participation in several September investor conferences. These include Citi's Annual BioPharma Conference (Sept 7-8), Morgan Stanley's Global Healthcare Conference (Sept 12-14), and H.C. Wainwright's Investment Conference (Sept 12-14) in New York. Founder and CEO Neil Desai will present and participate in discussions, with webcasts available on the company's website. Aadi continues to develop its pipeline after receiving FDA approval for FYARRO® in November 2021.
Aadi Bioscience reported net product sales of $3.4 million for FYARRO in Q2 2022, marking the first full quarter post-launch. The company is advancing the PRECISION 1 trial, with preliminary data expected in 1H23. Significant partnerships with genomic testing leaders were established to enhance patient recruitment for the trial. Despite a $3.7 million non-cash impairment charge and a net loss of $18.3 million for the quarter, cash reserves of $118.7 million are projected to fund operations into 2024.
FAQ
What is the current stock price of Aadi Bioscience (AADI)?
What is the market cap of Aadi Bioscience (AADI)?
